| Drug Name |
Eluxadoline |
| Drug ID |
BADD_D00761 |
| Description |
Eluxadoline is a mixed mu-opioid receptor agonist, kappa-opioid receptor agonist, and a-delta opioid receptor antagonist indicated for use in diarrhea-predominant irritable bowel syndrome (IBS-D). The mu-, kappa-, and delta-opioid receptors mediate endogenous and exogenous opioid response in the central nervous system and peripherally in the gastrointestinal system. Agonism of peripheral mu-opioid receptors results in reduced colonic motility, while antagonism of central delta-opioid receptors results in improved analgesia, making eluxadoline usable for the symptoms of both pain and diarrhea characteristic of IBS-D.
Marketed under the tradename Viberzi (FDA), eluxadoline is an antimotility agent that decreases bowel contractions, inhibits colonic transit, and reduces ？uid/ion secretion resulting in improved symptoms of abdominal pain and reductions in the Bristol Stool Scale. |
| Indications and Usage |
For the treatment of irritable bowel syndrome with diarrhea (IBS-D). |
| Marketing Status |
Prescription |
| ATC Code |
A07DA06 |
| DrugBank ID |
DB09272
|
| KEGG ID |
D10403
|
| MeSH ID |
C583636
|
| PubChem ID |
11250029
|
| TTD Drug ID |
D09ZXR
|
| NDC Product Code |
69766-020; 59651-330; 61874-075; 61874-100; 69037-0042 |
| Synonyms |
eluxadoline | Viberzi |
